Related Experiment Videos

Targeted therapies for adrenocortical carcinoma: IGF and beyond

Michael J Demeure1, Kimberly J Bussey, Lawrence S Kirschner

  • 1Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

Hormones & Cancer
|December 16, 2011
PubMed

Insights

New treatments for adrenocortical cancer (ACC) are needed. Targeting the insulin growth factor type 2 receptor (IGF1R) shows promise, with ongoing clinical trials evaluating novel agents against this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Adrenocortical cancer (ACC) has limited standard treatment options.
  • There is an urgent need for novel therapeutic agents to improve outcomes for ACC patients.
  • Molecular and genomic studies are identifying potential therapeutic targets in ACC.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for adrenocortical cancer.
  • To highlight the role of insulin-like growth factor 1 receptor (IGF1R) as a therapeutic target in ACC.
  • To discuss ongoing and future clinical trials for novel ACC treatments.

Main Methods:

  • Review of recent clinical trials and preclinical data for adrenocortical cancer treatments.
  • Focus on agents targeting the insulin growth factor type 2 receptor (IGF1R).
  • Discussion of emerging therapeutic strategies including tyrosine kinase inhibitors and personalized medicine.

Main Results:

  • Standard chemotherapy regimens are under evaluation.
  • Targeting IGF1R has shown encouraging results in preclinical models and early clinical studies.
  • Clinical trials evaluating IGF1R inhibitors (e.g., OSI-906) have been conducted.

Conclusions:

  • Targeting IGF1R represents a promising therapeutic strategy for adrenocortical cancer.
  • Further investigation into IGF1R antagonists and other tyrosine kinase inhibitors is warranted.
  • Personalized treatment approaches based on tumor analysis are on the horizon for ACC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...